Massey Quick & Co. LLC Has $152,000 Holdings in Gilead Sciences, Inc. (GILD)
Massey Quick & Co. LLC held its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,145 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Massey Quick & Co. LLC’s holdings in Gilead Sciences were worth $152,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also modified their holdings of GILD. Cincinnati Financial Corp acquired a new stake in Gilead Sciences during the 1st quarter worth about $63,737,000. Cincinnati Insurance Co. acquired a new stake in Gilead Sciences during the 1st quarter worth about $5,162,000. Cincinnati Specialty Underwriters Insurance CO acquired a new stake in Gilead Sciences during the 1st quarter worth about $2,853,000. Holderness Investments Co. acquired a new stake in Gilead Sciences during the 1st quarter worth about $272,000. Finally, State of Wisconsin Investment Board grew its position in Gilead Sciences by 9.9% during the 1st quarter. State of Wisconsin Investment Board now owns 1,767,160 shares of the biopharmaceutical company’s stock worth $120,025,000 after purchasing an additional 158,743 shares during the period. Hedge funds and other institutional investors own 76.23% of the company’s stock.
Gilead Sciences, Inc. (GILD) opened at $74.78 on Friday. The firm has a market cap of $97,660.00, a PE ratio of 7.58, a P/E/G ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the company posted $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.66%.
In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders sold a total of 458,486 shares of company stock worth $35,190,731 over the last three months. Corporate insiders own 1.30% of the company’s stock.
GILD has been the topic of several analyst reports. Berenberg Bank set a $96.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Royal Bank Of Canada initiated coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $81.00 price target (up from $73.00) on shares of Gilead Sciences in a research report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $85.22.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.